NVS
Novartis AG
PEG ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: NVS
- PEG Ratio
As of Jun 22, 2026, NVS's PE to growth ratio of 2.31 reflects its valuation relative to its growth rate. This result reflects a P/E ratio of 21.22 measured against EPS growth of 9.2%.
NVS PEG ratio history
Novartis AG's nine years historical PEG ratio has a mean of 0.47. Compared to historical data, NVS's 2.31 PEG ratio represents an increase of 391%. NVS hit its maximum PEG ratio of 2.37 during the Mar 2026 quarter over the last nine years. The Dec 2021 quarter marked the lowest reading at 0.04, indicating the most favorable growth-adjusted valuation.
Novartis AG PEG ratio by year
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| 2025 | 0.88 | 19.12 | 21.8% |
| 2024 | N/A | 16.44 | -17.2% |
| 2023 | 0.11 | 14.12 | 124.1% |
| 2022 | N/A | 28.44 | -70.2% |
| 2021 | 0.04 | 8.17 | 201.7% |
| 2020 | N/A | 26.6 | -30.7% |
| 2019 | N/A | 18.49 | -5.9% |
| 2018 | 0.24 | 15.77 | 65.9% |
| 2017 | 1.57 | 25.6 | 16.3% |
| 2016 | N/A | 25.83 | -61.9% |
| 2015 | 0.15 | 11.63 | 75.8% |
| 2014 | 1.83 | 22.01 | 12% |
| 2013 | N/A | 21.38 | -1.8% |
| 2012 | 7.87 | 16.53 | 2.1% |
| 2011 | N/A | 15.25 | -12.4% |
Novartis AG PEG ratio by quarter (TTM)
| Year | PEG ratio | PE ratio | Growth YoY |
|---|---|---|---|
| Mar 2026 | 2.37 | 21.76 | 9.2% |
| Dec 2025 | 0.88 | 19.12 | 21.8% |
| Sep 2025 | N/A | 17.42 | -14.3% |
| Jun 2025 | N/A | 17.54 | -12.2% |
| Mar 2025 | N/A | 17.34 | -12.8% |
| Dec 2024 | N/A | 16.44 | -17.2% |
| Sep 2024 | 0.1 | 13.39 | 129.7% |
| Jun 2024 | 0.12 | 13.54 | 117.1% |
| Mar 2024 | 0.11 | 13.12 | 124.7% |
| Dec 2023 | 0.11 | 14.12 | 124.1% |
| Sep 2023 | N/A | 27.24 | -61.8% |
| Jun 2023 | N/A | 27.88 | -64.8% |
| Mar 2023 | N/A | 28.05 | -69.6% |
| Dec 2022 | N/A | 28.44 | -70.2% |
| Sep 2022 | 0.06 | 7.77 | 124.3% |
NVS average PEG ratio chart
When comparing to historical data, NVS's PEG ratio sits above the 3, 5 and 10-year averages.
PEG comparison
With a PEG of 2.31, NVS stands higher than the Healthcare sector and the industry average. Looking at the Healthcare sector average of 0.55, Novartis AG's PEG is 320% higher.
NVS EPS growth
NVS Price vs fair value
NVS PEG vs peers
NVS reports a PEG ratio higher than that of peer stocks AZN and BMY.
| Stock name | PEG ratio | Market cap |
|---|---|---|
| TEVA Teva Pharmaceutical Industries Ltd | 0.11 | $37.49B |
| BMY Bristol Myers Squibb Co | 0.46 | $111.7B |
| AZN Astrazeneca plc | 0.78 | $273.29B |
| NVS Novartis AG | 2.31 | $284.17B |
| PFE Pfizer Inc | N/A | $142.94B |
| MRK Merck & Co Inc | N/A | $285.22B |
| JNJ Johnson & Johnson | N/A | $556.77B |
| ABT Abbott Laboratories | N/A | $152.98B |
Frequently asked questions
What is Novartis AG's PEG ratio?
NVS's Jun 22, 2026 PEG ratio comes in at 2.31.
What is the 3-year average PEG ratio for Novartis AG (NVS)?
NVS's 3-year PEG ratio average is 0.62.
What is the 5-year average PEG ratio for Novartis AG (NVS)?
NVS's 5-year PEG ratio average is 0.44.
What is the highest PEG ratio for NVS?
In the last nine years, NVS's peak PEG ratio of 2.37 occurred in the Mar 2026 quarter.
How does the current PEG ratio for NVS compare to its historical average?
At present, NVS's PEG ratio is 391% higher than its 9-year historical average.
Why is Novartis AG's PEG ratio so high?
When a company's earnings growth lags its valuation, the PEG ratio tends to be elevated - as seen with NVS's 2.31 reading.
How is NVS's PEG ratio calculated (Novartis AG PEG ratio formula)?
The PEG ratio derives from taking PE and dividing by the rate at which earnings are growing (YoY TTM). As of Jun 22, 2026, Novartis AG has a PE ratio of 21.22. Earnings grew at 9.2% over the TTM period ending Mar 2026. Applying the formula, this gives a PEG ratio of 2.31. PEG RATIO(2.31) = PE RATIO(21.22) / EPS GROWTH(9.2%)
All PEG ratio stats are based on quarterly TTM periods, unless otherwise specified.